Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial

Breast Cancer Research and Treatment

Volumn 139, Issue 3, 2013, Pages 751-758

  Bjohle J ^a   Bergqvist, J ^a   Gronowitz, J S ^b,c   Johansson, H ^a   Carlsson, L ^d   Einbeigi, Z ^e   Linderholm, B ^a,e   Loman, N ^f   Malmberg, M ^g   Soderberg M ^f   Sundquist, M ^h   Walz, T M ^a,i   Ferno M ^f   Bergh, J ^a   Hatschek, T ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Biovica International AB   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d Sundsvall General Hospital   (Sweden)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^f LUND UNIVERSITY   (Sweden)

^g Helsingborg General Hospital   (Sweden)

^h Kalmar General Hospital   (Sweden)

ⁱ LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Breast cancer; CA 15 3; DiviTum; Predictive factor; Prognostic factor; TK1

Indexed keywords

CA 15-3 ANTIGEN; CAPECITABINE; EPIRUBICIN; HORMONE; PACLITAXEL; THYMIDINE KINASE 1;

ADULT; AGE DISTRIBUTION; AGED; ANTIGEN DETECTION; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER PROGNOSIS; CELL PROLIFERATION; CONTROLLED STUDY; DISTANT METASTASIS; ELECTROCHEMILUMINESCENCE IMMUNOASSAY; ELISA KIT; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOASSAY; INOPERABLE CANCER; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MITOSIS RATE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PLEURA METASTASIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGIONAL METASTASIS; SKIN METASTASIS; SURVIVAL TIME; TREATMENT RESPONSE; VISCERAL METASTASIS;

ADULT; AGED; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; MUCIN-1; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SURVIVAL RATE; THYMIDINE KINASE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84879794180     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2579-x     Document Type: Article

References (33)

1. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC Jr (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25(33):5287-5312
2. Largillier R, Ferrero JM, Doyen J, Barriere J, Namer M, Mari V, Courdi A, Hannoun-Levi JM, Ettore F, Birtwisle-Peyrottes I et al (2008) Prognostic factors in 1,038 women with metastatic breast cancer. Ann Oncol 19(12):2012-2019
3. Beslija S, Bonneterre J, Burstein HJ, Cocquyt V, Gnant M, Heinemann V, Jassem J, Kostler WJ, Krainer M, Menard S et al (2009) Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 20(11):1771-1785
4. Solomayer EF, Diel IJ, Meyberg GC, Gollan C, Bastert G (2000) Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat 59(3):271-278
5. Foukakis T, Fornander T, Lekberg T, Hellborg H, Adolfsson J, Bergh J (2011) Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in Stockholm Sweden. Breast Cancer Res Treat 130(2):553-560
6. Cheung KL, Graves CR, Robertson JF (2000) Tumour marker measurements in the diagnosis and monitoring of breast cancer. Cancer Treat Rev 26(2):91-102
7. Ellis MJ, Suman VJ, Hoog J, Lin L, Snider J, Prat A, Parker JS, Luo J, DeSchryver K, Allred DC et al (2011) Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype-ACOSOG Z1031. J Clin Oncol 29(17):2342-2349
8. Topolcan O, Holubec L Jr (2008) The role of thymidine kinase in cancer diseases. Expert Opin Med diagn 2(2):129-141
9. Kim SR, Paik S (2011) Genomics of adjuvant therapy for breast cancer. Cancer J 17(6):500-504
10. Littlefield JW (1966) The use of drug-resistant markers to study the hybridization of mouse fibroblasts. Exp Cell Res 41(1):190-196
11. Weissman SM, Smellie RM, Paul J (1960) Studies on the biosynthesis of deoxyribonucleic acid by extracts of mammalian cells. IV. The phosphorylation of thymidine. Biochim Biophys Acta 45:101-110
12. Hu CM, Chang ZF (2007) Mitotic control of dTTP pool: a necessity or coincidence? J Biomed Sci 14(4):491-497
13. Munch-Petersen B, Cloos L, Jensen HK, Tyrsted G (1995) Human thymidine kinase 1. Regulation in normal and malignant cells. Adv Enzyme Regul 35:69-89
14. Broet P, Romain S, Daver A, Ricolleau G, Quillien V, Rallet A, Asselain B, Martin PM, Spyratos F (2001) Thymidine kinase as a proliferative marker: clinical relevance in 1,692 primary breast cancer patients. J Clin Oncol 19(11):2778-2787
15. Gronowitz JS, Bergstrom R, Nou E, Pahlman S, Brodin O, Nilsson S, Kallander CF (1990) Clinical and serologic markers of stage and prognosis in small cell lung cancer. A multivariate analysis. Cancer 66(4):722-732
16. Nisman B, Allweis T, Kaduri L, Maly B, Gronowitz S, Hamburger T, Peretz T (2010) Serum thymidine kinase 1 activity in breast cancer. Cancer Biomarkers 7(2):65-72
17. Nisman B, Yutkin V, Nechushtan H, Gofrit ON, Peretz T, Gronowitz S, Pode D (2010) Circulating tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nephrectomy. Urology 76(2):513.e1-513.e6
18. O'Neill KL, Hoper M, Odling-Smee GW (1992) Can thymidine kinase levels in breast tumors predict disease recurrence? J Natl Cancer Inst 84(23):1825-1828
19. Svobodova S, Topolcan O, Holubec L, Treska V, Sutnar A, Rupert K, Kormunda S, Rousarova M, Finek J (2007) Prognostic importance of thymidine kinase in colorectal and breast cancer. Anticancer Res 27(4A):1907-1909
20. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2006) Statistics Subcommittee of NCIEWGoCD: REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100(2):229-235
21. Hatschek T, Carlsson L, Einbeigi Z, Lidbrink E, Linderholm B, Lindh B, Loman N, Malmberg M, Rotstein S, Soderberg M et al (2012) Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial. Breast Cancer Res Treat 131(3):939-947
22. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205-216
23. WHO (1979) WHO Handbook for reporting results of treatment, 48th edn. World Health Organization, Geneva
24. Wu BJ, Li WP, Qian C, Ding W, Zhou ZW, Jiang H (2013) Increased serum level of thymidine kinase 1 correlates with metastatic site in patients with malignant melanoma. Tumour Biol 34(2):643-648
25. Romain S, Spyratos F, Descotes F, Daver A, Rostaing-Puissant B, Bougnoux P, Colonna M, Bolla M, Martin PM (2000) Prognostic of DNA-synthesizing enzyme activities (thymidine kinase and thymidylate synthase) in 908 T1-T2, N0-N1, M0 breast cancers: a retrospective multicenter study. Int J Cancer 87(6):860-868
26. Korkmaz T, Seber S, Okutur K, Basaran G, Yumuk F, Dane F, Ones T, Polat O, Madenci OC, Demir G et al (2013) Serum thymidine kinase 1 levels correlates with FDG uptake and prognosis in patients with non small cell lung cancer. Biomarkers 18(1):88-94
27. He Q, Fornander T, Johansson H, Johansson U, Hu GZ, Rutqvist LE, Skog S (2006) Thymidine kinase 1 in serum predicts increased risk of distant or loco-regional recurrence following surgery in patients with early breast cancer. Anticancer Res 26(6C):4753-4759
28. Robertson JF, O'Neill KL, Thomas MW, McKenna PG, Blamey RW (1990) Thymidine kinase in breast cancer. Br J Cancer 62(4):663-667
29. Gronowitz JS (1984) Extracellular expression of TK isozymes in human body fluids, with special reference to herpesvirus diagnostics and use for monitoring of antiviral therapy. In: Sanna A, Morace G (eds.) New Horizons in Microbiology. Amsterdam, Elsevier Science Publishers, p. 273-284
30. Foekens JA, Romain S, Look MP, Martin PM, Klijn JG (2001) Thymidine kinase and thymidylate synthase in advanced breast cancer: response to tamoxifen and chemotherapy. Cancer Res 61(4):1421-1425
31. Nisman B, Allweis T, Kadouri L, Mali B, Hamburger T, Baras M, Gronowitz S, Peretz T (2013) Comparison of diagnostic and prognostic performance of two assays measuring thymidine kinase 1 activity in serum of breast cancer patients. Clin Chem Lab Med 51(2):439-447
32. Yerushalmi R, Tyldesley S, Kennecke H, Speers C, Woods R, Knight B, Gelmon KA (2012) Tumor markers in metastatic breast cancer subtypes: frequency of elevation and correlation with outcome. Ann Oncol 23(2):338-345
33. Luporsi E, Andre F, Spyratos F, Martin PM, Jacquemier J, Penault-Llorca F, Tubiana-Mathieu N, Sigal-Zafrani B, Arnould L, Gompel A et al (2012) Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat 132(3):895-915